Felimazole 1.25mg Coated Tablets for Cats

Maa: Australia

Kieli: englanti

Lähde: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Osta se nyt

Lataa Pakkausseloste (PIL)
27-08-2020

Aktiivinen ainesosa:

THIAMAZOLE

Saatavilla:

DECHRA LTD

Lääkemuoto:

ORAL TABLET

Koostumus:

THIAMAZOLE UNGROUPED Active 1.25 mg/Tb

Kpl paketissa:

100 tablets

luokka:

VM - Veterinary Medicine

Terapeuttinen alue:

ENDOCRINE SYSTEM

Tuoteyhteenveto:

Poison schedule: 4; Withholding period: ; Host/pest details: CAT: [HYPERTHYROIDISM]

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

2023-07-01

Pakkausseloste

                                Felimazole 1.25 mg Coated Tablets for Cats
88436 / 121309
Product Name:
APVMA Approval No:
Constituent
Statements:
Each tablet contains 1.25 mg Thiamazole (Methimazole)
Contraindications:
Contraindicated for use in pregnant or lactating queens.
Contraindicated for use in cats suffering from systemic disease, such
as primary liver
disease or diabetes mellitus.
Contraindicated for use in cats showing signs of autoimmune disease.
Contraindicated for use in animals with disorders of white blood
cells, such as neutropaenia
and lymphopaenia.
Contraindicated for use in animals with platelet disorders and
coagulopathies (particularly
thrombocytopaenia).
Contraindicated for use in cats with hypersensitivity to thiamazole or
the excipient,
polyethylene glycol.
Claims:
Signal Headings:
Label Name:
Felimazole 1.25 mg Coated Tablets for Cats
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ SAFETY DIRECTIONS BEFORE OPENING OR USING
For the stabilisation of feline hyperthyroidism as a pre-operative
therapy.
For the long-term treatment of feline hyperthyroidism.
100 Tablets
Net Contents:
Directions for Use:
Restraints: RLP APPROVED
Precautions:
Concurrent treatment with phenobarbital may reduce the clinical
efficacy of thiamazole.
Concurrent treatment with benzimidazole wormers is known to reduce the
hepatic oxidation
of these actives and may lead to increases in circulating levels.
Thiamazole is immunomodulatory. Therefore, this should be taken into
account when
considering vaccination programmes.
Side Effects:
Side effects vary depending on dose regime and duration of treatment.
In a clinical field
study,
approximately
20%
of
the
cats
experienced
some
form
of
adverse
reaction,
most frequently when the product was used for long-term treatment of
hyperthyroidism. In
many cases, clinical signs were mild and transitory, and not a reason
for withdrawal of
treatment. The more serious effects were usually reversible when
medication was stopped.
At doses of up
to
15
mg,
clinical
side
effects
incl
                                
                                Lue koko asiakirja